nsclc.lungevity.org
Jun 1, 2025, 08:52
LUNGevity Foundation Highlighted FDA Approval on Telisotuzumab Vedotin (EMRELIS) in Advanced NSCLC
LUNGevity Foundation shared a post on LinkedIn:
“Despite the progress we have seen in the treatment of lung cancer, we need more options for people whose treatments stop working,” said Upal Basu Roy, PhD, MPH, executive director of research, LUNGevity Foundation. “This approval is a welcomed targeted therapy for those with high c-Met protein overexpressing late-stage, non-small cell lung cancer who have seen very limited treatment innovation in the last decade.”
Read More on nsclc.lungevity.org.
Read OncoDaily’s Special Article: FDA Approval for Telisotuzumab Vedotin (EMRELIS™)
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 18:07
Jun 2, 2025, 18:00
Jun 2, 2025, 17:43
Jun 2, 2025, 17:18
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20